PTK2 and neoplasm: Defactinib can inhibit FAK phosphorylation to ameliorate desmoplasia and reduce the formation of tumor stroma, thus synergistically facilitating the infiltration of cytotoxic T lymphocytes and decreasing Treg and M2 type macrophages.